Work Experience

March 2025 – Present: Professor, Jiangxi Science and Technology Normal University

May 2022 – Present: Founder and CEO, SynBioGene (Beijing) Biotechnology Co., Ltd.

July 2019 – April 2022: Vice President, Head of R&D, Harbin Pharmaceutical Group Co., Ltd.

January 2016 – July 2019: Founder & CEO, PharmEnjoy Technology (Beijing) Co., Ltd.

October 2012 – January 2016: Deputy General Manager, R&D Director, Yangtze River Pharmaceutical Group, Beijing Haiyan Pharmaceutical Co., Ltd.

February 2011 – September 2012: Senior Principal Scientist and Operations Director, BeiGene (Beijing) Biotechnology Co., Ltd.

2008 – 2011: Assistant Director, Medicinal Chemistry, PharmaLegacy (Beijing) Technology Co., Ltd.

1995 – 1998: Human Resources Management, Tianjin Institute of Printing Technology, Ministry of Machinery Industry

Educational Background

2006-2008 Postdoctoral Researcher, Auburn University, USA (Advisor: Prof. Stewart W. Schneller)

2004-2006 Postdoctoral Researcher, University of Missouri-St. Louis, USA (Advisor: Prof. Alexei V. Demchenko)

September 2001 - June 2004 Ph.D. in Medicinal Chemistry, School of Pharmaceutical Sciences / State Key Laboratory of Natural and Biomimetic Drugs, Peking University, China (Supervisors: Academician Lihe Zhang / Prof. Xinshan Ye)

September 1998 - June 2001 M.S. in Organic Chemistry, State Key Laboratory of Applied Organic Chemistry, Lanzhou University, China (Advisor: Prof. Longmin Wu)

September 1991 - June 1995 B.S., Department of Chemistry, Lanzhou University, China

Research Field

Research and Translation of Oligonucleotide

Major scientific research achievements

Mainly engaged in applied and fundamental research in the fields of oligonucleotide and peptide drugs. In recent years, has successively led/participated in four innovative drug discovery projects, filed three PCT international patent applications and over ten domestic patents, with two international innovative drug programs having entered clinical research. The R&D teams led and participated in have obtained over ten Clinical Trial Approvals and Production Approvals for Class 1 and Class 3 new drugs. Previously presided over a "Major New Drug Development" project under the Ministry of Science and Technology during the "12th Five-Year Plan" period. Has published nearly 30 papers in SCI-indexed professional journals and holds over 20 invention patents. Authored the academic book “跨国药企成功启示录”，“中国罕见病医疗产品发展蓝皮书”. Recognized as a National High-level Talent "Ten Thousand Talents Plan" Leading Scientific and Technological Talent (2024). Awarded the Third Prize of the Beijing Science and Technology Progress Award and the First Prize for Scientific and Technological Progress by the China Association of Chinese Medicine. Serves as an Adjunct Professor and Professional Master's Supervisor at the School of Pharmaceutical Sciences, Peking University, and an Adjunct Professor at Harbin Institute of Technology.

Mainly representing academic works/papers/patents

1. “Silver (I) Oxide Mediated Highly Selective Monoprotection of Diols in Pyranosides”, J. Org. Chem., 2004, 69 (17), 5774-5777.

2. “Iterative One-pot Oligosaccharide Synthesis of Oligosaccharides”, Angew. Chem. 2004, 116, 5333-5336；Angew. Chem. Int. Ed. 2004, 43, 5221-5224.

3. “Benzenesulfinyl morpholine: a new promoter for one-pot oligosaccharide synthesis using thioglycosides by pre-activation strategy”,  Synlett 2006, 17, 2846-2850.

4. “A new one-pot synthesis of Gb3 and isoGb3 trisaccharide analogues”, Tetrahedron 2006, 62(50), 11657-11662.

5. “Carbocyclic 4’-Epiformycin”, Tetrahedron 2008, 64(2), 433-438.

6. “Application of glycosyl thioimidates in polymer-supported oligosaccharide synthesis”, J. Org. Chem. 2008, 73(5), 1716-1725.

7. “Carbocyclic 4’-Deazaformycins”, Synthesis 2012, 23(5), 723-730.

8. “Preparation of 8-aza-7-deazaaristeromycin and -neplanocin A and their 5'-homologs.”  J. Heterocycl. Chem. 2015, 52(4), 1132-1135.

9. “Suhuang antitussive capsule at lower doses attenuates airway hyperresponsiveness,  inflammation, and remodeling in a  murine model of chronic asthma”, Scientific Reports, 2016, (6), 21515-21519

10. “Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis”, Bioorganic & Medicinal Chemistry Letters 2016, 26, 4077–4080.

11. “Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase” J. Med. Chem. 2019, 62, 7923−7940

12. “Guanosine-Based Self-Assembly as an Enantioselective Catalyst Scaffold” J. Org. Chem., 2020, 85, 4, 2010-2018.

13. “Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial” Frontiers of Medicine, 2021, 5, 704-717

14. “Novel NTCP ligand dimeric bile acid conjugated with ASO reduce hepatitis B virus surface antigen in vivo.” Euro. J. Med. Chem. 2024, 280, 116955-11695.

Patents

1. “Preparation of tricyclic calcium sensing receptor antagonists” From PCT Int. Appl. (2015), WO 2015095261.  

2. “Preparation of tricyclic calcium sensing receptor antagonists for the treatment of osteoporosis”From PCT Int.Appl. (2015), WO 2015089842.

3. “Method for preparing macroporous adsorbent resin” From (2016) , CN105622849 A 2016060

4. “Method for preparing amorphous alvimopan” From (2016), CN 105399659 A 20160316

5. “Application of peucedanum extract in improving immune function” From (2016)  CN 104997821 A 20151028

6. “A kind of amorphous Ivabradine hydrochloride and the preparation method” From (2015), CN 104829530 A 20150812

7. “Application of baiai capsule as cyp inhibitor” From (2015), CN 104523967 A 20150422

8. “Application of Cacumen Platycladi-Folium Artemisiae Argyi capsule as intestinal transporter inhibitor” From (2015),  CN 104435312 A 20150325

9. “Application of Platycladus orientalis leaf-Artemisia argyi leaf capsule as liver transporter inhibitor” From (2015), CN 104352632 A 20150218.

10. “Method for detecting antitussive Suhuang capsule” From (2014), CN 104007222 A 20140827.